NDA Acceptance in China for Fanregratinib

Summary by AI BETAClose X

HUTCHMED announced that its New Drug Application for fanregratinib for advanced intrahepatic cholangiocarcinoma with FGFR2 fusion/rearrangement has been accepted with priority review status by China's NMPA. This application is supported by Phase II trial data in China, which met its primary endpoint of objective response rate, with secondary endpoints also showing positive results. Fanregratinib is a novel, selective, oral inhibitor targeting FGFR 1/2/3, a pathway implicated in this aggressive form of liver cancer, which accounts for 8.2-15.0% of primary liver cancers and has a poor 5-year survival rate of approximately 9%.

Disclaimer*

UK 100

Latest directors dealings